Trajectories of Plasma Epstein-Barr Virus DNA and Clinical Outcomes in Recurrent or Metastatic Nasopharyngeal Carcinoma Treated With PD-L1 Inhibitors: A Post-Hoc Analysis of a Multicenter, Phase II Study. (PubMed, Head Neck) - Oct 13, 2026 - "This study suggests that plasma EBV DNA trajectories could be a promising biomarker for monitoring treatment response and longitudinal risk stratification."
Clinical data • IO biomarker • Journal • P2 data • Retrospective data • Epstein-Barr Virus Infections • Nasopharyngeal Carcinoma • Oncology • Solid Tumor
|
|
Jianming Diao; Junyou Ge; Kun Gao; Xingchen Peng; Yan Qing; Yiyan Pei; Youneng Wei; Zhen Pan
|